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The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia 
(AML) or high-risk myelodysplastic syndromes (MDS) remains unsatisfactory1-4.  
 Clofarabine is a purine nucleoside analog that is highly active as a single agent in 
AML5. Further, synergy between clofarabine and Ara-C has been demonstrated in vitro6 and 
in AML patients6-8. We have recently reported the results of the randomized phase I part of 
the EORTC/GIMEMA-AML-14A trial and identified clofarabine at 10 mg/m2/day on days 2, 
4, 6, 8 and 10 as the maximum tolerated dose (given either in a 1-h infusion or as push 
injection) in combination with Ara-C and idarubicin9. We decided to administer clofarabine 
on these 5 days because we hypothesized that the synergy between clofarabine and Ara-C 
would be more effective when clofarabine was present in the leukemic cells during the entire 
period of Ara-C administration. Further, we hypothesized that push injections of clofarabine 
might result in higher clofarabine peak levels than a 1-h infusion schedule, leading to a better 
interaction with Ara-C and more pronounced anti-leukemic effects. We herein report the final 
results of the combined phase I and II parts of the trial.  
EORTC/GIMEMA-AML-14A is an open label randomized 2-arm multicenter trial 
with a sequential phase I-II design (ClinicalTrial.gov: NCT00838240). The protocol was 
approved by the EORTC Protocol Review Committee and by the Ethical Committee of each 
participating center. The main objective of the phase II part of the trial was to explore the 
anti-leukemic activity of the aforementioned phase I selected dosage schedules of clofarabine 
given either as a 1-hour i.v. infusion (Arm A) or as a push injection (Arm B) over 10 minutes. 
The primary endpoint was the complete remission (CR)/CR with incomplete blood counts 
recovery (CRi) rate after 1 or 2 induction cycles. The aim was to determine whether, in each 
treatment group, the true CR/CRi rate was > 65% or not. Thus, for each of the arms A and B, 
the regimen was considered as active and feasible if ≥ 23/30 (76.7%) patients achieved a 
CR/CRi (see supplemental data for detailed study design and methods of statistical analyses). 
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Secondary endpoints included toxicity, overall survival (OS) from inclusion, OS from 
CR/CRi, relapse-free survival (RFS) from CR/CRi, and incidences of relapse and of death in 
CR/CRi.  
 Inclusion criteria included: age 18-60 years, primary or secondary intermediate or 
high-risk AML 10 or MDS with 10-19% blast cells in the bone marrow (BM), previously 
untreated disease, WHO Performance Status grade 0-2, and adequate organ functions. Main 
exclusion criteria included: good-risk AML (i.e. AML-M3, or AML with t(8;21) or inv(16)) 
and a white blood cell count (WBC) at diagnosis of <100 x109/L), blast crisis chronic myeloid 
leukemia or AML supervening a myeloproliferative disorder, central nervous system 
leukemia, evidence of severe concurrent cardiac, pulmonary, and neurological disorder, and 
uncontrolled infection.  
  Clofarabine was administered at 10 mg/m2 on days 2, 4, 6, 8 and 10 either as a 1-hour 
infusion (Arm A) or as a push injection (Arm B). Ara-C was administered at 100 mg/m2/day 
on days 1–10 as a continuous infusion, while idarubicin was given at 10 mg/m2/day on days 1, 
3, and 5 as a 5 minutes i.v. injection. A second identical course of induction chemotherapy 
was given in case of a partial response (PR). One cycle of consolidation chemotherapy 
consisting of Ara-C (500 mg/m2 every 12 hours as a 2-hour i.v. infusion on days 1-6) and 
idarubicin (10 mg/m2/day on days 4, 5 and 6) was administered in patients in both arms who 
achieved a CR/CRi. Post-consolidation treatment was left at the discretion of the local 
principal investigator, but it was recommended that the consolidation phase was followed by 
allogeneic hematopoietic cell transplantation (HCT) for patients with a HLA-identical related 
donor or for patients with very high-risk cytogenetics who had an HLA-compatible related or 
unrelated donor, or an autologous HCT in patients who were not candidate for allogeneic 
HCT1. 
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A total of 64 patients (12 in the phase I part and 52 in the phase II part of the study) 
were randomized at the dosage of clofarabine of 10 mg/m2/day (Supplemental Figure 1). Two 
patients had to be excluded because they did not meet the inclusion criteria. Among the 
remaining 62 patients, 41 had AML not otherwise specified, 11 AML with multilineage 
dysplasia, 5 therapy-related AML while 5 patients were diagnosed with MDS-RAEB2. 
Median age was 49.5 (range 20-60) years. Baseline characteristics were generally well 
balanced between the two arms (Table 1).  
  After 1 induction course, the CR/CRi rates were 26/31 patients in arm A (84%) versus 
25/31 patients in arm B (80%) (Table 2). The CR/CRi rate after 1 or 2 induction courses was 
84% (95% CI, 66-95%), in both arms, higher than the protocol-defined efficacy (>65%) 
(Table 2). Interestingly combining the results from both arms, the CR/CRi rate after 1 or 2 
courses of induction was similar in patients with very high-risk cytogenetics (11/13 patients 
(84.6%)), and in patients with normal or high risk cytogenetics (38/46 patients (82.6%)). 
These results are in the same range as those observed in two recent phase II studies 
investigating the efficacy of higher dosages of clofarabine combined with AraC (and 
idarubicin) as remission induction regimen for younger AML patients11, 12.   
   With a median follow-up of 1.8 (range, 1 – 5.3) years, 15/31 (48%) patients in arm A 
and 11/31 patients (36%) in arm B died. One-year OS from inclusion was 74% (95% CI, 55-
86%) in each arm, while median survival was 2.5 (1-not reached) years in arm A, versus not 
yet reached in arm B (Figure 1A).  
Consolidation chemotherapy was given in 26/26 patients who achieved a CR/CRi in 
arm A, and in 23/26 patients (88.5%) in arm B. Following consolidation chemotherapy, 12 of 
26 patients in arm A received an allogeneic HCT, while, in arm B, 14 patients received an 
allogeneic HCT and 2 an autologous HCT. Among a total of 52 patients in CR/CRi, 1-year 
OS and RFS from CR/CRi were 77% (95% CI, 56-89%) and 58% (95% CI, 37-74%), 
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respectively, in arm A versus 73% (95% CI, 51-86%) and 65% (95% CI, 44-80%), 
respectively, in arm B (Figure 1B). One-year incidences of relapse and of death in CR were 
23% (95% CI, 7-39%) and 19% (95% CI, 4-34%), respectively, in arm A, versus 19% (95% 
CI, 4-34%) and 15% (95% CI, 2-29%), respectively, in arm B (Figure 1 C-D). As expected, 
the incidence of relapse was higher in CR/CRi patients with very high risk cytogenetics (5/11: 
45%) than in those with intermediate/high risk cytogenetics (10/38: 26%). 
The toxicity profile of the two tested remission-induction chemotherapy regimens was 
acceptable and comparable in the two arms (Table 2), confirming data observed in the phase I 
of our study9. Median time to neutrophils ≥ 0.5x109/L and ≥ 1.0 x109/L were 28 (range, 22-
96) and 31 (range, 22-99+) days, respectively, in arm A, versus 27 (range, 20-50) and 29 
(range, 21-50) days, respectively, in arm B (Table 2). Further, median time to platelet levels ≥ 
20x109/L or ≥ 100x109/L were 28 (range, 24-83) and 31.5 (range, 24-99+) days, respectively, 
in arm A, versus 27 (range, 23-44) and 31 (range, 24-51) days, respectively, in arm B. Besides 
hematologic recovery, the grade > 2 toxicities observed in the AML-14A patients were in the 
same range as currently observed after standard remission-induction chemotherapy, with the 
possible exception of a higher incidence of grade > 2 hyperbilirubinemia that was observed in 
18% of the AML-14A patients. 
 We finally compared the outcomes of the AML14A patients to those of a subgroup of 
201 patients from the standard arm of the previous EORTC/GIMEMA-AML-12 study 
(combining standard dose Ara-C, daunorubicin and etoposide, see supplemental data)1 who 
met the same inclusion criteria as current patients, and were treated in the centers that 
contributed patients to the current AML14A study. As shown in the Supplemental table 1, 
patient characteristics were comparable in the 2 groups. However, since these analyses were 
not planned beforehand in the protocol they should be seen as indicative. The rate of CR/CRi 
after 1 or 1-2 cycles of induction chemotherapy were 82.3% and 83.9%, respectively, in 
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current AML14A patients versus 66.7% and 72.6%, respectively in the cohort of AML12 
patients (Supplemental Table 2). A higher proportion of patients included in the AML-14A 
(50%) than in AML-12 (30%) were offered an allogeneic HCT, probably reflecting at least in 
part the higher CR/CRi rate achieved in AML-14A patients. One-year OS and RFS rates were 
74.1% (95% CI, 61.3-83.3%) and 61.5% (95% CI, 47.0-73.2%), respectively, in current 
AML14 patients, and 58.0% (95% CI, 50.9-64.5%) and 54.1% (95% CI, 45.7-61.8%), 
respectively, in AML12 patients. Finally, among patients who reached a CR, the 1-year 
cumulative incidences of relapse and of death in CR were 23.3% and 17.3%, respectively, in 
AML-14A, as compared with 37.7% and 9.6%, respectively, in AML-12.  
In conclusion, the two tested clofarabine containing regimens yielded an impressive 
CR/CRi rate and encouraging 1-year OS/RFS rates among patients with intermediate/high-
risk AML or high-risk MDS. These results are worth confirming in a large phase III study. 
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Table 1. Baseline patients’ characteristics. 
 
 Treatment arm  
 1-hour infusion  
(Arm A, n=31) 
Push injection  
(Arm B, n=31) 
Total (n=62) 
    
Gender, # of patients (%)    
     Male    16 (51.6) 11 (35.5) 27 (43.5) 
     Female 15 (48.4) 20 (64.5) 35 (56.5) 
Age, years    
     Median 46.0 50.0 49.5 
     Range 20.0 - 60.0 22.0 - 60.0 20.0 - 60.0 
Presence of poor prognosis featuresa at 
randomization, # of patients (%)  
6 (19.4) 5 (16.1) 11 (17.7) 
WHO performance status, # of patients (%)    
    0 23 (74.2) 23 (74.2) 46 (74.2) 
    1 7 (22.6) 7 (22.6) 14 (22.6) 
    2 1 (3.2) 1 (3.2) 2 (3.2) 
WHO classification, # of patients (%)    
     AML with multilineage dysplasia 5 (16.1) 6 (19.4) 11 (17.7) 
     AML therapy related 2 (6.5) 3 (9.7) 5 (8.1) 
     AML not otherwise specified 23 (74.2) 18 (58.1) 41 (66.1) 
     MDS RAEB II                                       1 (3.2) 4 (12.9) 5 (8.1) 
Type of disease, # of patients (%)    
     De novo AML or MDS                                               29 (93.5) 28 (90.3) 57 (91.9) 
     Secondary AML or MDS                                             2 (6.5) 3 (9.7) 5 (8.1) 
WBC at diagnosis, # of patients (%)    
     < 100 x109/L 27 (87.1) 30 (96.8) 57 (91.9) 
     ≥ 100 x109/L 4 (12.9) 1 (3.2) 5 (8.1) 
Cytogeneticsb, # of patients (%)    
     Normal 19 (61.3) 13 (41.5) 32 (51.6) 
         With FLT3-ITD and unmutated/unk NPM1 3 (9.7) 3 (9.7) 6 (9.7) 
         Without FLT3-ITD and with mutated NPMI 6 (19.4) 5 (16.1) 11 (17.7) 
         With FLT3-ITD and with mutated NPMI 3 (9.7) 1 (3.2) 4 (6.5) 
         Other or unknown molecular markers  7 (22.6) 4 (12.9) 11 (17.7) 
     Good risk 0 0 0 
     High risk 3 (9.7) 10 (32.3) 13 (21) 
     Very high risk 8 (25.8) 5 (16.1) 13 (21.0) 
     Unknown/ failure / missing 1c (3.2) 3 (9.7) 4 (6.5) 
Bone marrow blasts (%)    
     Median 70 57 60.5 
     Range 19-97 12-99 12-99 
adefined as WBC at diagnosis ≥ 100 x 109/L or very high-risk cytogenetics or FLT3-ITD positivity; 
bCytogenetics: good risk includes inv(16) or t(8;21) ; very bad risk includes complex abnormalitis (>3 
abnormalities), monosomies 5, 7 and 5q-, 7q-, 3q, t(6;9), t(9;22), 11q23, t(9;11) ; bad risk includes all other 
chromosomal abnormalities; c 47,XY,dup(1)(q1?1q4?2),+8[7] / 46,XY,-17,+mar2[4] / 46,XY,-17,+mar1[3].  
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Table 2. Disease response (primary endpoint) and adverse events. 
 
 Treatment arm  
 1-hour infusion  
(Arm A, n=31) 
Push injection  
(Arm B, n=31) 
Total (n=62) 
Responsea to induction #1, # of patients (%)    
     CR   23 (74.2)           24 (77.4)        47 (75.8) 
     CRi    3 (9.7)             1 (3.2)          4 (6.5) 
     PR    1 (3.2)             1 (3.2)          2 (3.2) 
     Failure due to resistant disease 0 (0.0) 4 (12.9) 4 (6.5) 
     Failure due to complication from aplasia 2 (6.5) 1 (3.2) 3 (4.8) 
     Hypoplasia    1 (3.2)             0 (0.0)          1 (1.6) 
     Not assessable 1 (3.2) 0 (0.0) 1 (1.6) 
Response to inductions #1 / 2, # of patients (%)    
     CR 23 (74.2) 25 (80.6) 48 (77.4) 
     CRi 3 (9.7) 1 (3.2) 4 (6.5) 
     PR 1 (3.2) 0 (0.0) 1 (1.6) 
     Failure due to resistant disease 0 (0.0) 4 (12.9) 4 (6.5) 
     Failure due to complication from aplasia 2 (6.5) 1 (3.2) 3 (4.8) 
     Hypoplasia 1 (3.2) 0 (0.0) 1 (1.6) 
     Not assessable 1 (3.2) 0 (0.0) 1 (1.6) 
Most frequent (>5% in at least one arm) grade III-
IVb biochemical abnormalities, # of patients (%) 
   
     Bilirubin 4 (12.9) 6 (19.4) 10 (16.1) 
     ALT 4 (12.9) 4 (12.9) 8 (12.9) 
     Alkaline phosphatase 0 2 (6.5) 2 (3.2) 
Most frequent (>5% in at least one arm) grade III-
IVb adverse events, # of patients (%) 
   
     Febrile neutropenia 23 (74.2) 13 (41.9) 36 (58.1) 
     Documented infection 13 (42.0) 22 (70.9) 35 (56.5) 
     Anorexia 6 (19.4) 10 (32.3) 16 (25.8) 
     Diarrhea 7 (22.6) 6 (19.4) 13 (21.0) 
     Dyspnea 3 (9.7) 1 (3.2) 4 (6.5) 
     Fatigue 1 (3.2) 2 (6.5) 3 (4.8) 
     Rash 3 (9.7) 1 (3.2) 4 (6.5) 
     Nausea 2 (6.5) 1 (3.2) 3 (4.8) 
     Hemorrhage 3 (9.7) 0 3 (4.8) 
     Deshydratation 0 2 (6.5) 2 (3.2) 
Documented grade II-IV fungal infection, # of 
patients (%) 
4 (12.9) 9 (29.0) 13 (21.0) 
Causes of death    
     Acute myeloid leukemia 4 (12.9) 4 (12.9) 8 (12.9) 
     Toxicity 4 (12.9) 1 (3.2) 5 (8.1) 
     Transplant-related mortality 7 (22.6) 5 (16.1) 12 (19.4) 
      Other 0 1 (3.2) 1 (1.6) 
a) Evaluation of response was scheduled around day 31 after the start of the induction course. CR was defined as 
less than 5% marrow blasts and recovery of normal hematopoiesis with a neutrophil count ≥ 1 x109/L and a 
platelet count ≥ 100 x109/L in addition to disappearance of all clinical, laboratory, or radiological evidence of 
disease. The term incomplete CR (CRi) was used to define patients who met all CR criteria, but had neutrophil 
counts between 0.5 and 1.0 x109/L and/or platelet counts between 50 and 100 x109/L. Finally, partial remission 
(PR) was defined as 5-25% blast cells in the bone marrow and a reduction of at least 50% of blasts in the bone 
marrow, irrespective of count recovery. 








Figure 1. Overall Survival (A), Disease-free survival from CR (B), cumulative incidence of 
relapse from CR (C) and cumulative incidence of death in CR (D) in the 2 arms. 
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  and	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Study	  design	  The	  combined	  phase	  I	  and	  II	  part	  of	  the	  trial,	  exploring	  the	  efficacy	  of	  clofarabine	  of	  10	  mg/m2/day,	   was	   performed	   in	   8	   centers.	   After	   the	   maximum	   tolerated	   dose	   was	  reached	  in	  the	  phase	  I	  of	  the	  trial,	  additional	  patients	  were	  randomized	  in	  the	  phase	  II	  part	  of	  the	  trial	  using	  a	  1-­‐sample	  Fleming	  design.	  The	  statistical	  considerations	  were	  the	  following:	  P0	  was	  65%;	  P1	  was	  85%;	  beta	  error	  was	  0.05	  (actual	  one	  0.07)	  and	  alpha	  error	  was	  0.15	  (actual	  one	  0.12).	  Thus,	   for	  each	  of	   the	  arms	  A	  and	  B,	   the	  regimen	  was	  considered	  as	  active	  and	  feasible	  if	  ≥	  23/30	  (76.7%)	  patients	  achieved	  a	  CR/CRi.	  A	  total	  of	  30	  patients	  were	  required	  in	  each	  arm	  (24	  patients	  in	  addition	  to	  the	  6	  from	  the	  phase	  1	  of	  the	  trial	  using	  the	  same	  dosage	  of	  clofarabine).	  The	  protocol	  was	  approved	  by	  the	  EORTC	  Protocol	  Review	  Committee	  and	  by	  the	  Ethical	  Committee	  of	  each	  participating	  center.	  Patients	  were	  prospectively	  randomized	  at	   the	   EORTC	   Headquarters	   after	   signed	   written	   informed	   consent	   was	   obtained	  according	   to	   ICH/GCP	  and	  national/local	   regulations.	  Randomization	  was	   stratified	  by	  institution	  and	  by	  presence	  of	  any	  of	   the	   following	  poor	  prognostic	   features	  known	  at	  the	  time	  of	  inclusion:	  white	  blood	  cells	  (WBC)	  at	  diagnosis	  >=100	  x	  109/L,	  very	  high-­‐risk	  cytogenetics	  (defined	  as	  either	  monosomies	  5,	  7,	  or	  5q-­‐,	  7q-­‐,	  abn(3),	   t(6;9),	   t(9;22),	  or	  complex	  abnormalities	  (>3	  abnormalities)),	  or	  FLT3-­‐ITD	  positivity.	  	  	  
Comparison	  with	  a	  historical	  matched	  cohort	  of	  patients	  The	   rate	   of	   CR/CRi	   after	   1	   or	   2	   cycles	   of	   induction	   chemotherapy	   as	   well	   as	   OS	   and	  Relapse-­‐free	   survival	   (RFS)	   in	   the	   current	   study	   were	   compared	   with	   a	   cohort	   of	  comparable	   patients	   from	   the	   standard	   arm	   of	   the	   previous	   EORTC/GIMEMA	   study	  (AML-­‐12)1.	  They	  met	  the	  same	  inclusion	  criteria	  as	  current	  AML-­‐14A	  patients,	  and	  were	  from	  the	  centers	  that	  contributed	  patients	  to	  the	  current	  study.	  These	  analyses	  were	  not	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planned	  beforehand	  in	  the	  protocol.	  The	  standard	  arm	  of	  the	  AML-­‐12	  trial	  consisted	  of	  remission	  induction	  including	  Ara-­‐C	  (100	  mg/m2	  per	  day	  as	  continuous	  i.v.	  infusion	  for	  10	  days)	  plus	  daunorubicin	  (50	  mg/m2	  per	  day	  as	  a	  5-­‐minute	  push	  injection	  on	  days	  1,	  3,	  and	  5)	  plus	  etoposide	  (50	  mg/m2	  per	  day	  by	  1-­‐hour	  i.v.	  infusion	  on	  days	  1	  through	  5).	  Post-­‐remission	  consolidation	  therapy	  consisted	  of	  intermediate-­‐dose	  Ara-­‐C	  (500	  mg/m2	  every	   12	   hours	   as	   a	   2-­‐hour	   i.v.	   infusion	   on	   days	   1	   through	   6)	   plus	   daunorubicin	   (50	  mg/m2	  per	  day	  as	  a	  5-­‐minute	  push	  injection	  on	  days	  4	  through	  6).	  Recommended	  post-­‐consolidation	  treatment	  was	  as	  in	  the	  current	  protocol.	  	  	  	  
Stastistical	  analyses	  	  Time	  to	  hematologic	  recovery	  from	  the	  start	  of	  the	  first	  induction	  course	  was	  assessed	  in	  patients	  who	  achieved	  a	  CR/CRi.	  The	  duration	  of	  OS	  was	  calculated	  from	  the	  date	  of	  randomization	  until	   death.	  RFS	  was	   calculated	   as	   the	   time	   from	  CR/CRi	   until	   the	   first	  relapse	   or	   death.	   The	   Kaplan-­‐Meier	   method	   was	   used	   to	   estimate	   time-­‐to-­‐event	  outcomes.	  One-­‐year	  OS	  and	  RFS	  rates	  and	  medians	  were	  presented	  with	  95%	  confidence	  intervals	  (CI)	  based	  on	  the	  Brookmeyer	  and	  Crowley	  method2.	  Cumulative	  incidences	  of	  relapse	  or	  of	  death	  in	  CR/CRi	  were	  estimated	  from	  the	  date	  of	  CR/CRi	  achievement	  until	  either	  relapse	  or	  death	  without	  relapse	  by	  using	  competing	  risk	  methods2.	  Comparison	  of	   CR/CRi	   rate	   in	   current	   AML-­‐14A	   patients	   and	   in	   comparable	   historical	   AML-­‐12	  patients	  was	   carried	   out	  with	   Fisher’s	   exact	   test.	   SAS	   9.3	   software	   (SAS	   Institute	   Inc.	  Cary,	  NC)	  was	  used	  for	  the	  statistical	  analyses.	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Supplemental	  Results	  
	  
Supplemental	  figure	  1.	  Disposition	  of	  patients	  in	  each	  arm	  of	  AML-­‐14A	  study.	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Supplemental	  Table	  1.	  Baseline	  patients	  and	  historic	  controls	  (patients	  treated	  in	  the	  standard	  arm	  of	  the	  EORTC/GIMEMA	  AML-­‐12	  study)	  characteristics.	  	  	   Study	  	   AML-­‐14A	  
(n=62)	  
AML-­‐12	  
(n=201)	  	   	   	  
Gender,	  #	  of	  patients	  (%)	   	   	  	  	  	  	  	  Male	  	  	  	   27	  (43.5)	   100	  (49.8)	  	  	  	  	  	  Female	   35	  (56.5)	   101	  (50.2)	  
Age,	  #	  of	  patients	  (%)	   	   	  	  	  	  	  	  15-­‐45	  years	   26	  (41.9)	   91	  (45.3)	  	  	  	  	  	  46-­‐60	  years	   36	  (58.1)	   110	  (54.7)	  
WHO	  performance	  status,	  #	  of	  patients	  
(%)	  
	   	  	  	  	  	  0	   46	  (74.2)	   125	  (62.2)	  	  	  	  	  1	   14	  (22.6)	   67	  (33.3)	  	  	  	  	  2+	   2	  (3.2)	   9	  (4.5)	  
Type	  of	  disease,	  #	  of	  patients	  (%)	   	   	  	  	  	  	  	  De	  novo	  AML	  or	  MDS	   57	  (91.9)	   194	  (96.5)	  	  	  	  	  	  Secondary	  AML	  or	  MDS	   5	  (8.1)	   7	  (3.5)	  
WBC	  at	  diagnosis,	  #	  of	  patients	  (%)	   	   	  	  	  	  	  	  <	  100	  x109/L	   57	  (91.9)	   174	  (86.5)	  	  	  	  	  	  ≥	  100	  x109/L	   5	  (8.1)	   27	  (13.4)	  
Cytogeneticsa,	  #	  of	  patients	  (%)	   	   	  	  	  	  	  	  Good	  risk	  with	  >	  100x109	  WBC/L	  at	  diagnosis	   0	  (0)	   4	  (2)	  	  	  	  	  	  Normal	  (or	  –Y)	  without	  FLT3-­‐ITD	   22	  (35.5)	   83	  (41.3)	  	  	  	  	  	  High	  /	  very	  high	  risk	  or	  FLT3-­‐ITD	   36	  (58)	   90	  (44.8)	  	  	  	  	  	  Unknown/	  failure	  /	  missing	   4c	  (6.5)	   24	  (11.9)	  
Bone	  marrow	  blasts	  (%)	   	   	  	  	  	  	  	  Median	   60.5	   63.0	  	  	  	  	  	  Range	   12-­‐99	   2-­‐96	  aCytogenetics:	  good	  risk	  includes	  inv(16)	  or	  t(8;21)	  ;	  very	  bad	  risk	  includes	  complex	  abnormalitis	  (>3	  abnormalities),	  monosomies	  5,	  7	  and	  5q-­‐,	  7q-­‐,	  3q,	  t(6;9),	  t(9;22),	  11q23,	  t(9;11)	  ;	  bad	  risk	  includes	  all	  other	  chromosomal	  abnormalities.	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Supplemental	  table	  2.	  Comparison	  results	  from	  the	  AML14A	  study	  with	  a	  matched	  group	  of	  patients	  treated	  in	  the	  standard	  arm	  of	  the	  EORTC/GIMEMA	  AML-­‐12	  study	  1.	  	  	   Study	   P*	  	   AML-­‐14A	   AML-­‐12	   	  
#	  of	  patients	   62	   201	   	  
Response	  to	  induction	  #1,	  #	  of	  patients	  
(%)	  
	   	   	  	  	  	  	  	  CR	  /	  CRi	   51	  (82.3)	   134	  (66.7)	   0.025	  	  	  	  	  	  CR	  /	  CRi	  /	  PR	   53	  (85.5)	   153	  (76.1)	   	  	  	  	  	  	  Resistant	  disease,	  hypoplasia,	  death	   9	  (14.5)	   48	  (23.9)	   	  
Response	  to	  inductions	  #1	  /	  #2,	  #	  of	  
patients	  (%)	   	   	   	  	  	  	  	  	  CR	  /	  CRi	   52	  (83.9)	   146	  (72.6)	   0.092	  	  	  	  	  	  PR,	  resistant	  disease,	  hypoplasia,	  death	   10	  (16.1)	   55	  (27.4)	   	  
Allogeneic	  transplantation	  in	  CR1,	  #	  of	  
patients	  [%]**	   26	  [50.0]	   43	  [29.5]	   	  
One-­‐year	  outcomes,	  %	  (95%	  CI)	   	   	   	  	  	  	  	  	  	  Overall	  survival	  rate	   74.1	  (61.3	  -­‐	  83.3)	   58.0	  (50.9	  -­‐	  64.5)	   	  
	  	  	  	  	  	  Relapse-­‐free	  survival	  rate**	   61.5	  (47.0	  -­‐	  73.2)	   54.1	  (45.7	  -­‐	  61.8)	   	  	  	  	  	  	  	  	  	  	  	  	  	  Relapse	  incidence**	  	   23.3	  (11.7	  –	  34.8)	   37.7	  (29.8	  –	  45.5)	   	  	  	  	  	  	  	  	  	  	  	  	  	  Death	  in	  CR	  incidence**	   17.3	  (7.0	  –	  27.6)	   9.6	  (4.8	  –	  14.4)	   	  *:	  Using	  the	  Fisher’s	  exact	  test	  **:	  Computed	  in	  patients	  who	  reached	  CR	  after	  induction	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